@article{93f903e29a14496081bf3d187cdb1423,
title = "Longitudinal Evolution of Cardiac Dysfunction in Heart Failure and Preserved Ejection Fraction With Normal Natriuretic Peptide Levels",
keywords = "Diastolic, Heart atria, Heart failure, Natriuretic peptides, Pro-brain natriuretic peptide",
author = "Hidemi Sorimachi and Verbrugge, {Frederik H.} and Kazunori Omote and Massar Omar and Masaru Obokata and Reddy, {Yogesh N.V.} and Zi Ye and Michelena, {Hector I.} and Borlaug, {Barry A.}",
note = "Funding Information: Dr Borlaug is supported by R01 HL128526 and U01 HL160226 from the National Institutes of Health, and W81XWH2210245, from the US Department of Defense. Dr Verbrugge is supported by a Fellowship of the Belgian American Educational Foundation (B.A.E.F.) and by the Special Research Fund (BOF) of Hasselt University (BOF19PD04). Funding Information: Dr Borlaug has received research grants from AstraZeneca, Axon, GlaxoSmithKline, Medtronic, Mesoblast, Novo Nordisk, and Tenax Therapeutics, along with consulting fees from Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations. Dr Borlaug is named inventor on an issued patent (US Patent no. 10 307 179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. The other authors report no conflicts.",
year = "2022",
month = aug,
day = "9",
doi = "10.1161/CIRCULATIONAHA.121.058592",
language = "English (US)",
volume = "146",
pages = "500--502",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",
}